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Although head and neck carcinoma ranks fifth among cancer types, patient survival rates have 
not changed significantly over the past years.
Objective: To determine the risk factors, causes, therapies, and prevention measures for head and 
neck cancer.
Method: Risk factors, causes, therapies, and preventive measures for this disease were searched on 
databases PUBMED, MEDLINE, and SciELO.
Results: Alcohol and tobacco are still atop risk factors. Other factors may influence the development 
of head and neck carcinoma. Surgery is the main treatment option, and the addition of radiotherapy 
following surgery is frequent for patients in the early stages of the disease. Other therapies target 
specific genetic molecular components connected to tumor development. Disease preventive 
measures include smoking cessation, limiting alcohol intake, preventing exposure to tobacco smoke 
and environmental carcinogenic agents, early detection of infection by HPV, maintaining oral health, 
good eating habits, and managing stress.
Conclusion: Additional research is needed for a more thorough understanding of the development 
of head and neck carcinomas and to shed light on new ways to improve therapeutic approaches 
and interventions.
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INTRODUCTION
Head and neck squamous cell carcinoma 
(HNSCC) that comprising upper aerodigestive tract 
anatomic sites represents the third common cause 
of cancer death in worldwide. For the year 2009, 
approximately 47,000 HNSCC cases were estimated 
and 11,000 deaths from the disease were expected1.
The vast majority (more than 90%) are squa-
mous cell carcinomas, and the disease typically 
appears in the oropharynx, oral cavity, hypopha-
rynx, or larynx. The development of HNSCC is 
the result of the interaction of both environmental 
factors and genetic inheritance, and is therefore, 
multifactorial. Smoking and alcohol abuse are major 
risk factors for the development of this disease2.
Human papillomavirus (HPV) is also con-
sidered risk factor in about 25% of the disease. 
HPV infection has a known role in oropharyngeal 
carcinogenesis, particularly in tonsillar cancer, 
with strong and independent prognostic, probably 
because they determine the molecular profile of 
the cancer and thus the response to therapy. At 
the same time, not all smokers and alcohol users 
develop HNSCC, suggesting that individual varia-
tion in genetic susceptibility plays a critical role3. 
Preliminary results suggest that high-risk HPV infec-
tions seem to be biologically relevant in laryngeal 
carcinogenesis, however, the clinical significance of 
these infections and the implications in the disease 
prevention and treatment are unclear and require 
further investigation4.
The 5-year life expectancy is about 50% 
when there are lymphnode metastases5. It was 
demonstrate previously that cure rates in patients 
with advanced disease using tumor response to 
neoadjuvant chemotherapy is efficient. This is im-
portant because of the treatment intensity in future 
protocols so as to achieve the best cure rates with 
the least toxicity6. Nowadays, there are new surgical 
techniques, such as through robotic surgery, that 
decreases the tracheotomy rate, and allows a faster 
oral swallowing recovery and shorter hospital stay7.
The radiotherapy and concomitant chemotherapy 
also had been demonstrate better survival rates 
for laryngeal preservation and locoregional con-
trol8. Mortality and morbidity associated with these 
malignancies remains high, causing an impact on 
the quality of life and also in the treatment cost of 
these patients9. The head and neck cancer disease 
can affect overall and mental health, appearance, 
employment, social life and family living. Also may 
occur serious changes in the functioning of the 
upper aero digestive tract that affect the life quality 
of patients Furthermore, the understanding of disea-
se development and its appearance can help in the 
treatment choice, as well as the symptoms analysis 
and/or rehabilitation necessary, better organization 
and quality of care, identifying aspects of impact 
on patient survival in help of the decision on the 
effectiveness of treatment through the clarification 
of the side effects of treatment. Based on the above 
data, this review focuses on recent advances related 
to causes, prevention, treatment, clinical aspects 
and outcomes in HNSCC.
OBJECTIVE
To determine risk factors, causes, treatment 
and prevention of head and neck cancer through 
of the research in database (PUBMED, SciELO, 
MEDLINE).
METHOD
We researched all papers published in the 
literature, regardless of year of publication, with 
following key words: “Head and neck cancer”, 
“Head and neck cancer and prevention”, “Head and 
neck cancer and causes”, “Head and neck cancer 
and treatment”, “Head and neck cancer and survival 
life”, “Head and neck cancer and tobacco”, “Head 
and neck cancer and alcohol”. In this study, we 
researched only papers that evaluated malignancies 
located in the upper aero digestive tract (oral cavity, 
pharynx and larynx cancer).
Head and neck cancer causes
Tobacco smoking is well established as a 
dominant risk factor for HNSCC, and this risk is cor-
related with the intensity and duration of smoking 
habit4,10. The cigarette contains nitrosamines and 
polycyclic hydrocarbons carcinogens elements that 
have genotoxic effects and therefore may increase 
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the risk of disease. These elements can change 
the molecular profile of the individuals and cause 
mutations.
The study of Kumar et al.11 showed that 
smoking cessation reduces but does not eliminate 
the risk of cancer development, However, Marron 
et al.12 confirmed that cessation of tobacco smoking 
protect against the HNSCC development. The major 
risk factor for oral cancers among non-drinkers is 
tobacco use and among nons-mokers is alcohol 
use13,14. The risk may increase directly with alcohol 
concentration (eg, consumption of spirits vs beer 
or wine), even after adjustment for total alcohol 
consumed. It is currently unclear whether the type 
of alcohol used affects the oral cancer risk after 
adjustment for total amount consumed and alcohol 
concentration14,15.
Alcohol acts as a solvent to enhance mucosal 
exposure to carcinogens, increasing cellular uptake 
of these. The acetaldehyde, a metabolite of alcohol, 
can form DNA adducts, that interfere with DNA syn-
thesis and repair16. According Marur & Forastiere17, 
the consumption of tobacco associated with alcohol 
consumption increases the HNSCC risk 40-fold. At 
the same time, not all smokers and alcohol users 
develop HNSCC, suggesting that individual variation 
in the genetic susceptibility plays a critical role3. 
Furthermore, there is a strong relationship between 
alcohol and tobacco use and the combined use of 
these further increases the risk14.
Recent data confirms that infection with HPV-
16 is an independent risk factor for HNSCC, main-
ly for oropharyngeal squamous cell carcinoma18. 
In addition, high-risk HPV types (HR HPV) are a 
risk factors in about 25% of HNSCC, independent 
of other known risk factors, such as alcohol and 
tobacco10. Although the mode of transmission of 
HPV in head and neck cancer has not been deter-
mined, sexual behavior has been associated with 
an increased risk19. Moreover, the presence of viral 
DNA in tumors, the etiological link between HPV 
and head and neck cancer has been supported by 
the detection of HPV DNA in oral rinses and HPV-
-specific antibodies in head and neck cancer cases19.
The diet can be associated with decreased 
risk for the disease. Diet has strong evidence with 
cancer development and data confirm a probable 
causal relationship for a decreased HNSCC risk with 
non-starchy vegetables, fruits, and food containing 
carotenoids. A recent study confirmed that higher 
dietary pattern scores, with high consumption of 
fruit and vegetable and low intake of red meat, were 
associated with HNSCC reduced risk20.
Carcinogen exposure, oral hygiene, dental 
plaque formation, chronic irritation to the lining 
of the mouth, family history, low body mass index 
and exposure to ultraviolet light also all play a role, 
individually or in combination, in the HNSCC deve-
lopment, because they can modulate toxin and car-
cinogenic metabolism21-23.The carcinogen exposure 
increases the HNSCC risk because the carcinogens 
smoke has genotoxic effects. The cigarette has 
approximately 4,700 substances, and at least 50 of 
these are carcinogenic, including nitrosamines and 
polycyclic hydrocarbons24. Regarding oral hygiene, 
the polymicrobial supragingival plaque may be con-
sidered as a possible independent factor because 
it has a relevant mutagenic interaction with saliva, 
and individual oral health may be a co-factor in 
the development of oral cavity carcinomas. Perio-
dontal diseases resulting from poor oral hygiene 
can lead to infections with consequent release of 
inflammatory mediators such as cytokines and the 
reactions against inflammation can promote cancer 
development. The loss of teeth can also contribute 
for oral cancer development, it leads for alteration 
of oral flora favors the reduction of nitrites and ni-
trates and the production of acetaldehyde, which 
leads to the formation of DNA adducts21-24.
The influence of family history in HNSCC 
development may be because familial aggrega-
tions that may indicate that inheritable genetic 
factors play a role in HNSCC risk22. Several genetic 
polymorphisms in genes involved in the carcino-
gens metabolism, DNA repair or in several other 
processes have been associated with HNSCC risk, 
although the results were not always consistent. 
Since the differential ability to metabolize carcino-
gens happens only when exposure occurs, it is also 
possible that the familial risk reflects both a higher 
genetic susceptibility for HNSCC together with an 
aggregation of exposures22.
In a pooled analysis of 17 international stu-
dies, it was found that lean subjects were at higher 
242
Brazilian Journal of otorhinolaryngology 79 (2) March/april 2013
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
risk for HNSCC, whereas heavy subjects were at a 
lower risk, compared with subjects with a normal 
body size, after adjustment for major HNSCC risk 
factors (smoking and drinking). One possible expla-
nation is that, in the time shortly before diagnosis, 
undiagnosed cancer lesions in the head and neck 
may cause dysphagia or odynophagia or may alter 
taste and appetite, leading to a reduction of overall 
caloric intake and weight loss. The reduced risk 
among overweight people may indicate body size 
is a modifier of the risk associated with smoking 
and drinking. Further clarification may be provided 
by analyses of prospective cohort23.
Occupational activity also appears to be as-
sociated with HNSCC development. The study by 
Conway et al.25 showed that manual occupational 
activities, low income, low occupational-social class, 
low educational attainment and unemployment 
correlate with increased risk for disease develop-
ment. The individuals who work in rural activities 
are in constant exposure to sunlight and in contact 
with carcinogenic substances that contribute to the 
development of oral cavity cancer26.
Head and neck cancer treatment
The use of surgery, radiation, and/or che-
motherapy depends on tumor respectability and 
location, as well as whether an organ preservation 
approach is feasible.27 The main treatment option 
for primary and secondary malignancy as well as 
recurrent disease is surgical therapy28. The use of 
transoral laser assisted surgery followed by radio-
therapy is a common practice in the treatment of 
early stage oropharyngeal, hypopharyngeal and 
supraglottic carcinomas29. On the other hand early 
glottic carcinomas show excellent oncologic results 
after single modality treatment. Transoral laser sur-
gery is the treatment of choice but radiotherapy is 
also a good alternative30.
Although obtaining negative surgical margins 
is the primary goal of head and neck surgery, achie-
ving this may be impossible in some cases because 
of infiltration of vital structures such as the carotid 
artery or the prevertebral fasciae. The positive 
surgical margin status is associated with decreased 
survival, therefore a patient should be re-operated if 
the tumor was not removed completely31. However, 
achieving negative margins can cause impairment 
in important functions such as chewing, swallowing 
and speech, and adversely affect quality of life32. 
Therefore primary radiochemotherapy is an alter-
native for patients with advanced head and neck 
carcinomas.
Recommendation of planned neck dissection 
regardless of clinical response is supported by the 
high rates of residual disease observed in planned 
neck dissection surgical specimens and the data 
shows improved regional control and survival with 
planned neck dissection33. Advances in imaging 
techniques may help identify those patients with a 
clinical partial response for whom a planned neck 
dissection can be omitted. Until then, we recom-
mend that patients achieving less than a clinical 
partial response after chemoradiation proceed to 
planned neck dissection34.
In general, there are 3 main approaches to 
the initial treatment of locally advanced disease: (1) 
concurrent platinum-based chemoradiation, with 
surgery reserved for residual disease; (2) surgery 
with neck dissection and reconstruction, followed 
by adjuvant radiation or chemoradiation, depending 
on the presence of adverse risk factors; or (3) in-
duction chemotherapy followed by definitive che-
moradiation and/or surgery Approximately 60% of 
patients with HNSCC present at a locally advanced 
stage, in which combined modality therapy with 
curative intent is recommended27,35.
Cisplatin remains the cornerstone of treatment 
in recurrent and metastatic HNSCC. Moreover, pos-
toperative concurrent administration of high-dose 
cisplatin with radiotherapy is more efficacious than 
radiotherapy alone in patients with locally advan-
ced HNSCC and does not cause an undue number 
of late complications36. Data shows that radiation 
therapy combined with simultaneous 5-fluorouracil 
(5-FU), cisplatin, carboplatin, and mitomycin C as 
single drug or combinations of 5-FU with one of 
the other drugs results in a large survival advantage 
irrespective the employed radiation schedule. If 
radiation therapy is used as single modality, hyper-
fractionation leads to a significant improvement 
of overall survival. Accelerated radiation therapy 
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alone, especially when given as split course radia-
tion schedule or extremely accelerated treatments 
with decreased total dose, does not increase overall 
survival37.
Cetuximab in combination with platinum/5-
FU has emerged as a new alternative regimen for 
untreated patients based on results from the first-
line Treatment of Recurrent or Metastatic Head and 
Neck Cancer trial. Cetuximab can be used with 
chemotherapy in first-line treatment of recurrent 
or metastatic disease, and in second-line treatment 
of platinum-refractory disease35. The data from a 
phase III trial support the role of cetuximab plus 
radiotherapy as an effective treatment option for 
patients with locoregionally advanced HNSCC. 
Moreover, cetuximab plus radiotherapy led to 
significant improvements in locoregional control 
and survival and these survival improvements may 
be maintained long-term, with a nine percentage 
point advantage for cetuximab plus radiotherapy 
in the 5-year overall survival rate, compared with 
radiotherapy alone. The combination of cetuximab 
and concurrent chemoradiotherapy is currently 
being investigated in phase III trials. Incorporation 
of cetuximab into sequential chemotherapy 
and radiotherapy/chemoradiotherapy regimens 
is yielding interesting results. After induction 
chemotherapy, the combination of cetuximab and 
radiotherapy was better tolerated than platinum-
based concurrent chemoradiotherapy with a similar 
short-term rate of larynx preservation38.
The taxanes docetaxel and paclitaxel (Taxol®) 
are active in HNSCC. Several phase II studies have 
indicated that adding a taxane improves responsi-
veness to 5-FU based induction chemotherapy. Re-
sults of a randomized phase III trial that compared 
induction chemotherapy using docetaxel and 5-FU 
together with 5-FU alone indicated that incorpo-
ration of a taxane substantially improves clinical 
response and survival in locally advanced head and 
neck cancer. However, paclitaxel may be develop 
neurotoxicity and be problematic, particularly when 
used in combination with other neurotoxic agents 
such as cisplatin39.
Regarding to radiotherapy (RT), RT intensity 
modulated (IMRT) has increasingly been shown to 
be advantageous compared with traditional techni-
ques such as conventional RT (2D) and conforma-
tion (3D), in that it provides a more homogeneous 
coverage of dose to the target volume and a de-
crease in the dose in the surrounding tissues. The 
highest dose is related with better tumor control 
and better survival rates40.
There is also hyperfractionated radiation the-
rapy utilized in patients with HNSCC. However, this 
treatment option can develop reaction of different 
intensities in the mucosa, as oral mucositis, that cau-
ses significant pain, chewing and swallowing diffi-
culties and is considered the most debilitating acute 
reaction during head and neck cancer treatmen41. 
The use of brachytherapy treatment in patients with 
HNSCC, that use radiation sources in direct contact 
with the tissues to be irradiated, increase the risk to 
develop soft tissue necrosis, which may be defined 
as an ulcer located in the radiated tissue, without 
the presence of residual malignancy42.
Actually, there are novel therapies that target 
specific molecular components that can improve 
understanding of the molecular genetic for HNSCC. 
For example, the EGFR (Epidermal growth factor 
receptor), that overexpress more than 90% in the 
HNSCC, a central transducer of multiple signaling 
pathways is involved in tumor cell growth, angioge-
nesis, and invasion. There are different points along 
this signal transduction sequence and the therapy 
can target in an effort to blockade EGFR function. 
If this blockade occur in combination with other 
treatment modalities, for example the inhibition of 
other signaling pathways, the EGFR blockade may 
be most successful11.
The availability of biologic therapies that 
target mechanisms important in tumor growth and 
metastasis has led to efforts to personalize therapy 
based on specific patient or tumor characteristics. 
Studies have included either subgroup or correlative 
analyses of such characteristics with outcome35,43. 
Interdisciplinary collaboration and case discussions 
should take place in the context of a tumor board. 
Further progress may be expected as new insights 
are obtained about key mechanisms and prognostic 
factors involved in HNSCC.
Head and neck cancer prevention
New approaches are helping to elucidate 
long-recognized but poorly understood biologic 
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concepts such as field cancerization and are help-
ing to explain perplexing clinical patterns such as 
local tumor recurrence following seemingly com-
plete resection44. Analysis of the molecular genetic 
changes in the HNSCC discloses not just individual 
tumor differences, but also consistent large-scale 
differences that permit the recognition of important 
subtypes of HNSCC. The novel treatment strategies 
can be improve these differences that to enhance 
immunologic responses to tumor-specific antigens 
and to target individual components of the molecu-
lar genetic apparatus45.
A number of definitive risk factors such as 
smoking, HPV infection and key genetic altera-
tions including EGFR, TP53, p16, p14 were identi-
fied and many will be discovered in the coming 
years. In the current context, by quitting cigarette 
smoking, limiting alcohol drinking, avoiding to-
bacco chewing, preventing exposure to second 
hand tobacco smoke, environmental carcinogens, 
screening for HPV, maintaining good oral health, 
nutritional habits and managing stress could be 
good primary measures for preventing or delaying 
HNSCC development46. However, data are discon-
tented and demonstrated that smoking and etilism 
maintenance and/or recurrence rates are high in 
patients treated for HNSCC, meaning only patient 
advice is not enough as a strategy leading to these 
habit cessation47.
The poor prognosis for HNSCC is primarily 
due to disease detection at advanced stages. There-
fore, the understanding of the field cancerization 
and the molecular genetics of HNSCC is essential 
to provide better intervention and therapeutic ap-
proaches, thus introducing various biomarkers 
with potential application for diagnosing, staging, 
monitoring, and prognosticating2.
The diet can also influence in neoplasias 
development due to the way in which they are 
prepared and the additives used. Certain foods 
having antitumoral properties, such cruciferous 
plants (cauliflower, broccoli and cabbage), they 
blocked enzymes responsible for tumoral activa-
tion or chelation (sequestering) of the free radicals, 
an enhanced detoxification process that alters the 
activity of these enzymes or else the modulation of 
certain DNA repair processes48. Therefore, a regular 
diet may prevent or delay the HNSCC development.
Although there is data showing instruments 
for preventing head and neck cancer, it is necessary 
for further clarification more studies for detection 
of the new prognostic indicators, which could be 
used in diagnostics.
RESULTS
Alcohol and smoking remain the major risk 
factors and have an additive effect. However, the-
re are other factors that also influence the HNSCC 
development as HPV infection, diet, carcinogen 
exposure, oral hygiene, infectious agents, family his-
tory, low body mass index, exposure to ultraviolet 
light, chronic irritation to the lining of the mouth 
and dental plaque formation, preexisting medical 
conditions and occupational activity.
The main treatment option for primary and 
secondary malignancy as well as recurrent disease 
is surgical therapy and the use of surgical practice 
followed by radiotherapy is a common practice 
in the treatment for HNSCC in early stages of the 
disease (I or II) with a high percentage of cure. 
There are also novel therapies that target specific 
components of the molecular genetic apparatus 
supporting tumor development and growth.
The quitting cigarette smoking, limiting alco-
hol drinking, avoiding tobacco chewing, preventing 
exposure to second hand tobacco smoke, environ-
mental carcinogens, screening for HPV, maintaining 
good oral health, nutritional habits and managing 
stress could be good primary measures for preven-
ting or delaying HNSCC development.
DISCUSSION
The HNSCC is the fifth leading cause of de-
ath in the world population, with an incidence of 
500,000 new cases per year. In recent years, the 
management of head and neck cancer has been 
more complex with combined-modality programs, 
as well as the integration of new diagnostic and 
therapeutic technologies20.
Nowadays, it is known that is not only 
smokers and drinkers that may develop HNSCC, 
although they still have a great influence. There 
are many other risk factors that are involved in the 
HNSCC appearance, for this reason it is necessary 
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to investigate the origin of the disease in each 
patient. Thereby, the choice of treatment may be 
more specific. HNSCC is the most complex “organ 
site”, so the treatment decision is not an oversta-
tement, and supports a best practices model of 
multidisciplinary team involvement. Surgery is often 
required, followed by treatment of a radiotherapy 
or chemotherapy.
Surgery may be disfiguring and psychologi-
cally traumatic, however, there are methods that can 
preserve the organs, such as preservation of man-
dibule, because the mandibule has important roles 
in functional, aesthetic, psychological aspects of the 
human. The conservative mandibulectomy techni-
ques presents favorable results49. There are another 
rehabilitation methods, as rehabilitation methods 
reconstruction of all cervicofacial post-excision 
defects and reconstruction using osteomyocutanous 
grafts and microanastomosis50. Although there sur-
gery options for organ preservation, these methods 
still have limitation and needs more investigations.
Chemotherapy, either induction therapy or 
concurrent chemoradiotherapy, is routinely inte-
grated into the treatment of patients with locally 
advanced head and neck cancer. Sequential therapy 
incorporating both induction chemotherapy and 
chemoradiation is a feasible approach and has the 
potential to further improve survival outcomes39. 
However, higher doses of the chemotherapies or 
radiotherapy can be lead to many collateral effects 
that can be prejudicial and affect the life quality of 
patients.
Nowadays, the most effective measures to 
improve the prognostic of the malignant tumors 
are prevention and early diagnosis. The early de-
tection and initial treatment are successfully treated 
when HNSCC is discovered. If not detected early 
may require treatments ranging from surgery for its 
removal to radiotherapy or chemotherapy.The main 
problem is that disinformation and non-compliance 
of the symptoms by the patients, and lack of routine 
examinations by health professionals are causes of 
late diagnosis of tumor. Therefore, this leads to a 
stronger treatment that can impair life quality of the 
patient due to HNSCC as one of the most aggressive 
and mutilating tumor.
CONCLUSION
Although there are established risk factors, it 
is known that there are many other factors that may 
contribute to HNSCC development. There are diffe-
rent types of treatment for HNSCC according to the 
disease stage. Some have already been confirmed 
to increase survival of patients, however, all types 
of treatment (surgery, chemotherapy, radiotherapy 
and chemoradiotherapy) lead to side effects that 
may impair the patient’s life and mutilation of cer-
tain organs. New insights for intervention and the-
rapeutic approaches are needed to more complete 
understanding of HNSCC development.
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